Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Humphries
Karin H
KH
Department of Medicine, University of British Columbia and Centre for Health Evaluation & Outcomes Sciences, Vancouver, BC. khumphries@providencehealth.bc.ca <khumphries@providencehealth.bc.ca>
Kerr
Charles R
CR
Steinbuch
Michael
M
Dorian
Paul
P
D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002170:Canada; D000075202:Contraindications; D005260:Female; D005424:Flecainide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D012042:Registries; D013015:Sotalol / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D011405:Propafenone; D013015:Sotalol; D011802:Quinidine; D005424:Flecainide; D000638:Amiodarone